EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.
Through 9 successful Joint Transnational Calls launched from 2009 to 2018, EuroNanoMed has allocated about 76 Million euros to fund 87 transnational projects in nanomedicine.
Under the umbrella of EuroNanoMed III, the 10th Joint Transnational Call is launched for funding multilateral innovative research projects on nanomedicine.
- Opening of the submission system: 14thDecember 2018
- Submission deadline for pre-proposals: 31stJanuary 2019
- Submission deadline of full proposals: 1stJuly 2019
Electronic submission website
Research project consortia who intend to submit a transnational proposal should register at https://ptoutline.eu/app/euronanomed2019, clicking the “to register” button and following the directions. The system will be opened by December 14th, 2018. To register, please complete the different sections as soon as possible. Electronic proposal submission of proposals on the indicated website is mandatory.
Contact details for the Joint Call Secretariat:
- JCS 2019 is hosted by The National Institute of Health Carlos III
- Monforte de Lemos, 5; 28029 Madrid, Spain
- Contact person for the Joint Call Secretariat: María Druet
- Email: email@example.com; Phone: +34 9182 22530
- Call text
- Guidelines for applicants
- Pre-proposal submission form
- Pre-eligibility check form for ITALIAN RESEARCHERS
AIM of the call
The aims of the call are:
- To support translational research projects that combine innovative approaches in the field of nanomedicine and;
- To encourage and enable transnational collaboration between public and private research groups from academia (research teams from universities, higher education institutions, public research institutions) and clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations) or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs (Small and Medium-size Enterprises) is strongly encouraged.
TOPICS of the call
Project proposals will address multidisciplinary and translational research. The project proposals must cover at least one of the following areas that are equal in relevance for this call:
- Regenerative medicine
- Targeted delivery systems
Applicants are asked to specify to which of the two categories described below the project falls, according to its TRL, degree of innovation and expected time to market:
- Innovation applied research projects: Proof of concept projects for innovative applications with analytical/experimental research and/or implementation and integration of components and test in laboratory and/or animal models. Safety and nanotoxicity should be taken into account when relevant. The viability of a path that may lead the experimental and/or analytical results (for TRL 3) and/or demonstrators (for TRL 4) to a future application at medium/long term shall also be demonstrated.
- Projects with high potential of applicability at short/medium term: Projects closer to the market for the validation of demonstrators and prototypes in a realistic laboratory (for TRL 5) and/or relevant simulated operational field environment (for TRL-6). The viability of a path that may lead the validated systems and results to real products shall be demonstrated. Industrial engagement is crucial in this type of projects. Medical regulatory aspects have to be properly considered.
General conditions for application
Joint research proposals may be submitted by applicants belonging to one of the following categories:
- A – Academia (research teams working in universities, other higher education institutions) or research institutes;
- B – Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
- C – Enterprise (private companies of all sizes). Participation of Small and Medium-size Enterprises (SMEs) is encouraged.
Each application should include partners from at least two of the three categories A, B and C. Each consortium submitting a proposal must involve a minimum of three eligible and a maximum of five eligible partners from at least three different countries participating to the. The maximum number of partners can be increased from five to seven under certain circumstances. No more than two eligible partners from the same country participating in the call will be accepted in one consortium.
Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organization respective of the country/region from which applicants have applied. The applications are therefore subjected to eligibility criteria of individual funding organizations. Please note that the national eligibility conditions have evolved since the last EuroNanoMed call. Applicants are therefore strongly advised to contact their national representative as soon as possible in order to confirm their eligibility with their respective funding organizations.
Looking for partners?
Have a look at the European Nanomedicine Map!
- Ignacio Baanante
- +34 9182 22576
About EuroNanomed III
EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine. Through 9 successful Joint Transnational Calls launched from 2009 to 2018, ENM has allocated about 75,4 Million euros to fund 87 transnational and innovative research projects in nanomedicine.
EuroNanoMed III is funded under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission, Research Directorate-General, Grant Agreement No. 723770